Dear Investor,

We are pleased to invite you to an exclusive, invitation-only investor reception on Tuesday, September 30 in New York City featuring i-Lumen Scientific, a pioneering ophthalmology company redefining the treatment landscape for Dry Age-related Macular Degeneration (Dry-AMD).

Unlike current therapies that merely slow the disease, i-Lumen’s patented, non-invasive microcurrent stimulation technology is designed to restore visual acuity, offering a first-in-class, vision-restoring solution for the 130M+ people worldwide suffering from Dry-AMD. In a recent U.S. feasibility study, over 50% of patients improved by 10+ letters on the ETDRS eye chart in just 90 days.

With a large unmet market, strong clinical signal, and a clear FDA pathway, i-Lumen is positioned to become a category-defining company and a prime acquisition target.

The Investment Opportunity:

• Series B raise: $24 million
• Valuation: $31.5M pre-money / $57.6M post-money
• Use of funds: Pivotal i-SIGHT2 trial, FDA filing, commercial readiness

Why i-Lumen?

Vision-Restoring Sciencei-Lumen’s dual-waveform transpalpebral neuromodulation uniquely targets Müller and RPE cells—delivering functional vision gains in early to intermediate-stage Dry-AMD. The i-SIGHT feasibility trial showed clear superiority over sham, with improvements in both visual acuity and retinal anatomy.

Massive, Underserved MarketDry-AMD affects 1 in 4 people over 60, with no FDA-approved therapies for early/intermediate stages. i-Lumen’s scalable, in-office solution addresses a $68.5B+ global market, with a CPT-reimbursable business model that mirrors the success of LASIK.

Clear Path to FDA Clearance and AcquisitionBacked by a team with 16 FDA-cleared devices and $850M in exits, i-Lumen is targeting Class II De Novo clearance by 2028, with active acquisition discussions already underway with strategic buyers including Alcon, J&J, Zeiss, and Bausch.

Patent-Protected, High-Margin Revenue ModelWith 29 U.S. patents and an estimated 90% gross margin on disposables, the company’s razor/razor-blade model supports high recurring revenue through physician-delivered treatments.

Why Attend:This is a rare opportunity to invest in the last independent, early-stage player with meaningful clinical data in a space ripe for consolidation. With strong IP, validated science, and a de-risked FDA strategy, i-Lumen offers the potential for 12–15x return multiples based on recent ophthalmology M&A activity.Join us for an insider’s view into how i-Lumen is creating a paradigm shift in vision restoration and meet the leadership team powering this transformation.

Event Details – Strictly LimitedLocation: The Capital GrilleAddress: 200 Park Ave, New York, NY 10166Date: Tuesday, September 30, 2025Time: 5:30 PM EDTRSVP now to secure your seat and request investor materials by contacting:Skylar Rallison at srallison@opus8.com

We look forward to seeing you in New York for an evening of groundbreaking science, strategic vision, and investment opportunity.

Thanks much and all the best,

The Opus8 Team